bacTRL™ Platform Technology

Symvivo’s bacTRL™ platform technology is a genetically modified probiotic bacteria.  Used as a single dose and administered via intravenous injection, bacTRL™ selectively colonizes primary and secondary solid tumors while simultaneously being cleared from healthy tissues.  As the colony is maintained in the tumor microenvironment, bacTRL™ produces and delivers genetic material to the surrounding tumor tissues throughout the life of the colony.  As a result, the bacTRL™ platform dramatically out-performs pre-existing gene delivery technologies, providing superior rates of gene delivery coupled with highly specific tumor gene delivery.